Shanshan Wei, Zhihao Huang, Huizhen Xiong, Ji Wu, D. Mei, Jing Zhao, Wei Liu, Qingyun Liu, Yu Lin, Fang Liu, Xiang Peng, Honglei Chen
2026.1.1HELICOBACTER
tlooto Summary
The eradication rate of the KA regimen with esomeprazole‐based bismuth quadruple therapy (EBQT) containing amoxicillin and clarithromycin for H. pylori initial eradication in the Chinese population is compared.
Abstract
The efficacy of keverprazan–amoxicillin dual therapy (KA) in the treatment of Helicobacter pylori (H. pylori) has not yet been demonstrated. Here, we aimed to compare the eradication rate of the KA regimen with esomeprazole‐based bismuth quadruple therapy (EBQT) containing amoxicillin and clarithromycin for H. pylori initial eradication in the Chinese population.
Citation format
WEI, Shanshan, et al. Efficacy and safety of keverprazan–amoxicillin dual regimen in initial eradication of helicobacter pylori infection: A multicenter, randomized controlled trial. HELICOBACTER, 2026, 31(1): e70100.